Potent and broad-spectrum antimicrobial activity of CXCL14 suggests an immediate role in skin infections

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 507-514

  Maerki, Christa ^a   Meuter, Simone ^c   Liebi, Mark ^a   Mühlemann, Kathrin ^b   Frederick, Mitchell J ^d   Yawalkar, Nikhil ^b   Moser, Bernhard ^c   Wolf, Marlene ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL14 CHEMOKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; POLYPEPTIDE ANTIBIOTIC AGENT; ALPHA CHEMOKINE; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; CXCL14 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROBIAL IMMUNITY; NONHUMAN; PH; PRIORITY JOURNAL; SKIN CANDIDIASIS; SKIN INFLAMMATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C3H MOUSE; CANDIDIASIS; CELL FREE SYSTEM; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; GENETICS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY; SKIN INFECTION; TUMOR CELL LINE;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDIASIS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL-FREE SYSTEM; CHEMOKINES, CXC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; SKIN DISEASES, INFECTIOUS;

EID: 59849115871     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.507     Document Type: Article

References (40)

1. Bos, J. D., and M. L. Kapsenberg. 1993. The skin immune system: progress in cutaneous biology. Immunol. Today 14: 75-78.
2. Schaerli, P., and B. Moser. 2005. Chemokines: control of primary and memory T-cell traffic. Immunol. Res. 31: 57-74.
3. Moser, B., M. Wolf, A. Walz, and P. Loetscher. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25: 75-84.
4. Schaerli, P., L. Ebert, K. Willimann, A. Blaser, R. S. Roos, P. Loetscher, and B. Moser. 2004. A skin-selective homing mechanism for human immune surveillance T cells. J. Exp. Med. 199: 1265-1275.
5. Ebert, L. M., S. Meuter, and B. Moser. 2006. Homing and function of human skin γδ T cells and NK cells: relevance for tumor surveillance. J. Immunol. 176: 4331-4336.
6. Sleeman, M. A., J. K. Fraser, J. G. Murison, S. L. Kelly, R. L. Prestidge, D. J. Palmer, J. D. Watson, and K. D. Kumble. 2000. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR α-chemokine. Int. Immunol. 12: 677-689.
7. Kurth, I., K. Willimann, P. Schaerli, T. Hunziker, I. Clark-Lewis, and B. Moser. 2001. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J. Exp. Med. 194: 855-861.
8. Frederick, M. J., Y. Henderson, X. Xu, M. T. Deavers, A. A. Sahin, H. Wu, D. E. Lewis, A. K. El-Naggar, and G. L. Clayman. 2000. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am. J. Pathol. 156: 1937-1950.
9. Schaerli, P., K. Willimann, L. M. Ebert, A. Walz, and B. Moser. 2005. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23: 331-342.
10. Shellenberger, T. D., M. Wang, M. Gujrati, A. Jayakumar, R. M. Strieter, M. D. Burdick, C. G. Ioannides, C. L. Efferson, A. K. El-Naggar, D. Roberts, et al. 2004. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 64: 8262-8270.
11. Shurin, G. V., R. L. Ferris, I. L. Tourkova, L. Perez, A. Lokshin, L. Balkir, B. Collins, G. S. Chatta, and M. R. Shurin. 2005. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174: 5490-5498.
12. Meuter, S., P. Schaerli, R. S. Roos, O. Brandau, M. R. Bosl, U. H. von Andrian, and B. Moser. 2007. Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues. Mol. Cell. Biol. 27: 983-992.
13. Braff, M. H., A. Bardan, V. Nizet, and R. L. Gallo. 2005. Cutaneous defense mechanisms by antimicrobial peptides. J. Invest. Dermatol. 125: 9-13.
14. Brown, K. L., and R. E. Hancock. 2006. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18: 24-30.
15. Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3: 710-720.
16. Izadpanah, A., and R. L. Gallo. 2005. Antimicrobial peptides. J. Am. Acad. Dermatol. 52: 381-390.
17. Niyonsaba, F., and H. Ogawa. 2005. Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents β-defensins, cathelicidin LL-37 and lysozyme. J. Dermatol. Sci. 40: 157-168.
18. Schroder, J. M., and J. Harder. 2006. Antimicrobial skin peptides and proteins. Cell Mol. Life Sci. 63: 469-486.
19. Yang, D., A. Biragyn, L. W. Kwak, and J. J. Oppenheim. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23: 291-296.
20. Hoover, D. M., C. Boulegue, D. Yang, J. J. Oppenheim, K. Tucker, W. Lu, and J. Lubkowski. 2002. The structure of human macrophage inflammatory protein-3α /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human β-defensins. J. Biol. Chem. 277: 37647-37654.
21. Cole, A. M., T. Ganz, A. M. Liese, M. D. Burdick, L. Liu, and R. M. Strieter. 2001. Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity. J. Immunol. 167: 623-627.
22. Krijgsveld, J., S. A. Zaat, J. Meeldijk, P. A. van Veelen, G. Fang, B. Poolman, E. Brandt, J. E. Ehlert, A. J. Kuijpers, G. H. Engbers, et al. 2000. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J. Biol. Chem. 275: 20374-20381.
23. Yang, D., Q. Chen, D. M. Hoover, P. Staley, K. D. Tucker, J. Lubkowski, and J. J. Oppenheim. 2003. Many chemokines including CCL20/MIP-3α display antimicrobial activity. J. Leukocyte Biol. 74: 448-455.
24. Hieshima, K., H. Ohtani, M. Shibano, D. Izawa, T. Nakayama, Y. Kawasaki, F. Shiba, M. Shiota, F. Katou, T. Saito, and O. Yoshie. 2003. CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J. Immunol. 170: 1452-1461.
25. Starner, T. D., C. K. Barker, H. P. Jia, Y. Kang, and P. B. McCray, Jr. 2003. CCL20 is an inducible product of human airway epithelia with innate immune properties. Am. J. Respir. Cell Mol. Biol. 29: 627-633.
26. Linge, H. M., M. Collin, P. Nordenfelt, M. Morgelin, M. Malmsten, and A. Egesten. 2008. The human CXC-chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane disrupting properties and is antibacterial. Antimicrob. Agents Chemother. 52: 2599-2607.
27. Gallo, R. L., M. Murakami, T. Ohtake, and M. Zaiou. 2002. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110: 823-831.
28. Zasloff, M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
29. Clark-Lewis, I., L. Vo, P. Owen, and J. Anderson. 1997. Chemical synthesis, purification, and folding of C-X-C and C-C chemokines. Methods Enzymol. 287: 233-250.
30. Liu, T. J., W. W. Zhang, D. L. Taylor, J. A. Roth, H. Goepfert, and G. L. Clayman. 1994. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 54: 3662-3667.
31. Wu, Z., D. M. Hoover, D. Yang, C. Boulegue, F. Santamaria, J. J. Oppenheim, J. Lubkowski, and W. Lu. 2003. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human β-defensin 3. Proc. Natl. Acad. Sci. USA 100: 8880-8885.
32. Ali, R. S., A. Falconer, M. Ikram, C. E. Bissett, R. Cerio, and A. G. Quinn. 2001. Expression of the peptide antibiotics human β defensin-1 and human β defensin-2 in normal human skin. J. Invest. Dermatol. 117: 106-111.
33. Nakayama, T., R. Fujisawa, H. Yamada, T. Horikawa, H. Kawasaki, K. Hieshima, D. Izawa, S. Fujiie, T. Tezuka, and O. Yoshie. 2001. Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 α/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int. Immunol. 13: 95-103.
34. Ong, P. Y., T. Ohtake, C. Brandt, I. Strickland, M. Boguniewicz, T. Ganz, R. L. Gallo, and D. Y. Leung. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347: 1151-1160.
35. Schauber, J., R. A. Dorschner, K. Yamasaki, B. Brouha, and R. L. Gallo. 2006. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118: 509-519.
36. Schittek, B., R. Hipfel, B. Sauer, J. Bauer, H. Kalbacher, S. Stevanovic, M. Schirle, K. Schroeder, N. Blin, F. Meier, et al. 2001. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat. Immunol. 2: 1133-1137.
37. Singh, P. K., H. P. Jia, K. Wiles, J. Hesselberth, L. Liu, B. A. Conway, E. P. Greenberg, E. V. Valore, M. J. Welsh, T. Ganz, et al. 1998. Production of β-defensins by human airway epithelia. Proc. Natl. Acad. Sci. USA 95: 14961-14966.
38. Glaser, R., J. Harder, H. Lange, J. Bartels, E. Christophers, and J. M. Schroder. 2005. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat. Immunol. 6: 57-64.
39. Elias, P. M. 2007. The skin barrier as an innate immune element. Semin. Immunopathol. 29: 3-14.
40. Cogen, A. L., V. Nizet, and R. L. Gallo. 2008. Skin microbiota: a source of disease or defense? Br. J. Dermatol. 158: 442-455.